12 registrations that name quercetin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 12 registrations
Status
Phase
15US sites across 8 states
1
2 to 4
5 to 19
20 or more
All 12 registrations
RecruitingNCT07303894
A Study of Isoquercetin in People With Ovarian Cancer
Phase 2
Memorial Sloan Kettering Cancer Center
About 90 people
Started Jan 22, 2026
In plain words A Phase 2 study of quercetin in people 18 and older, run by Memorial Sloan Kettering Cancer Center. It plans to enroll about 90 people at 8 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Serous Ovarian Tumor.
Participants must have histological- or cytological-confirmed ovarian cancer (epithelial, serous, or clear cell) and be receiving first-line chemotherapy (day 1 of isoquercetin should align with day 1 of cycle 1 or 2 of chemotherapy) for…
Minimum age 18 years
Life expectancy of greater than 6 months.
ECOG performance status <2
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Isoquercetin; Placebo
Registered summary
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Where, as registered
8 US sites in 3 states.
RecruitingNCT05653258
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Phase 2 and 3
Cedars-Sinai Medical Center
About 160 people
Started Oct 17, 2023
In plain words A Phase 2 and 3 study of quercetin in people 18 and older, run by Cedars-Sinai Medical Center. It plans to enroll about 160 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Obesity; Healthy Lifestyle.
Both Sexes
Age: younger lean group 18-30 years with BMI 18.5-24.9 kg/m2; younger obese group 18-30 with BMI 30.0 -39.9; older obese group ≥ 65 years with BMI 30.0-39.9
All races and ethnic groups
Community dwelling
4 more inclusion criteria and the exclusion criteria are on the listing.
All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).
Where, as registered
1 US site in 1 state.
RecruitingNCT07760506
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
No phase
Applied Science & Performance Institute
About 60 people
Starts Sep 18, 2026 (estimated)
In plain words A study of quercetin in people 50 to 75, run by Applied Science & Performance Institute. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 75; healthy volunteers accepted. Conditions: Healthy Aging; Inflammaging; Metabolic Health; Quercetin; Coenzyme Q10.
Males and females aged 50 to 75 years
Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of…
BMI of > or equal to 25.00kg/m²
Individuals with > or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https://www.cdc.gov/prediabetes/takethetest)
8 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements. The main questions it aims to answer are: 1. Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo? 2. What side effects, if any, do participants have while taking these supplements? Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient). The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06940297
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Mayo Clinic
About 44 people
Started Sep 18, 2025
In plain words A Phase 2 study of quercetin in people 18 and older, run by Mayo Clinic. It plans to enroll about 44 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Recurrent Multiple Myeloma; Refractory Multiple Myeloma.
Age ≥ 18 years
Relapsed or refractory multiple myeloma who has had at least 3 prior lines of therapies including a proteasome inhibitor, immunomodulatory drug (IMiD) and anti-CD38 monoclonal antibody (mAb)
Ciltacabtagene autoleucel (Carvykti) available for patient
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
16 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07025226
Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease
Early phase 1
Mayo Clinic
About 30 people
Started Aug 12, 2025
In plain words An early phase 1 study of quercetin in people 18 and older, run by Mayo Clinic. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Glioma.
Age ≥ 18 years
Prior diagnosis of a glioma treated with chemotherapy and/or radiation with stable disease based on Response Assessment in Neuro-Oncology (RANO) criteria
Must have IDH-mutant OR MGMT-methylated glioma
NOTE: Patients with any radiographic evidence of residual disease are eligible
20 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Biospecimen Collection; Dasatinib; Fisetin; Magnetic Resonance Imaging; Patient Observation; Positron Emission Tomography; Quercetin; Temozolomide; Topoisomerase-1 Inhibitor LMP744; Single Agent Therapy
Registered summary
This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin, temozolomide, LMP744, and autologous tumor lysate particle only (TLPO) vaccine work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07433621
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
Phase 1
Children's Hospital Medical Center, Cincinnati
About 12 people
Started Feb 26, 2026
In plain words A Phase 1 study of quercetin in male participants 2 and older, run by Children's Hospital Medical Center, Cincinnati. It plans to enroll about 12 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 2 and older. Conditions: XIAP Deficiency.
Male patients
Diagnosis of XIAP deficiency
Patients ≥2 years of age
Serum IL-18 ≥600 pg/mL (approximately 25% above the lab-defined upper limit of normal of 477 pg/mL)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Quercetin
Registered summary
The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.
In plain words A Phase 1 study of quercetin in people 2 and older, run by Children's Hospital Medical Center, Cincinnati. It plans to enroll about 12 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 2 and older. Conditions: Dyskeratosis Congenita; Telomere Disease.
Diagnosis of DC/TBD deficiency as defined by at least one of the following:
Age adjusted mean-telomere length of <1 percentile in all tested peripheral blood cells such as granulocytes, lymphocytes, B-cells, naïve T-cells, memory T-cells, and NK cells
A pathogenic or likely pathogenic mutation in DKC1, TERC, TERT, NOP10, NHP2, TINF2, CTC1, PARN, RTEL1, ACD, NAF1, ZCCHC8, or WRAP53
Patients ≥ 2.0 years of age*
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Quercetin
Registered summary
The purpose of this study is to see if a vitamin-like substance called quercetin is safe for people who have a rare condition called Dyskeratosis congenita (DC) or telomere biology disorders (TBD).
Where, as registered
1 US site in 1 state.
RecruitingNCT07182526
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Phase 2
Al-Mustansiriyah University
About 150 people
Starts Sep 20, 2025 (estimated)
In plain words A Phase 2 study of quercetin in people 18 and older, run by Al-Mustansiriyah University. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries.
• Newly diagnosed patients should be at reproductive aged from 18-40 years.
Patients diagnosed with presence of micro polycystic ovaries at ultrasound.
Oligomenorrhea with inter-menstrual intervals longer than 35 days.
Clinical or biochemical signs of hyperandrogenism (acne, hirsutism).
1 more inclusion criterion and the exclusion criteria are on the listing.
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. The full summary is on the listing.
Where, as registered
No US site; Iraq (1).
RecruitingNCT07466420
Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
No phase
Katerina M. Antoniou
About 100 people
Started Jan 26, 2026
In plain words A study of quercetin in people 18 and older, run by Katerina M. Antoniou. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Fibrotic Interstitial Lungs Diseases; Idiopathic Pulmonary Fibrosis (IPF); Progressive Pulmonary Fibrosis.
Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study.
The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care.
The exclusion criteria are on the listing.
What it tests, as registered
Quercetin (dietary supplement); Usual treatment
Registered summary
Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung function, respiratory failure, and high mortality, despite the currently approved antifibrotic treatment. While its exact cause remains unknown, pulmonary fibrosis is strongly linked to aging, genetic predisposition, environmental factors, and cellular senescence. The full summary is on the listing.
Where, as registered
No US site; Greece (1).
RecruitingNCT06230861
Effects of Quercetin on Cardiometabolic Outcomes
No phase
University of Central Lancashire
About 40 people
Started Mar 1, 2024
In plain words A study of quercetin in people 18 to 65, run by University of Central Lancashire. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Cardiometabolic Syndrome.
Healthy
Between 18 \& 65 years
BMI < 30
Able to give informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Quercetin; Placebo
Registered summary
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.
Where, as registered
No US site; United Kingdom (1).
RecruitingNCT07487623
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
No phase
University of Guadalajara
About 26 people
Started Oct 11, 2025
In plain words A study of quercetin in people 18 to 69, run by University of Guadalajara. It plans to enroll about 26 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 69. Conditions: Liver Disease Chronic; HEPATITIS C VIRUS CHRONIC INFECTION.
What it tests, as registered
resveratrol, quercetin, taurine, whey protein, and inulin; whey protein
Registered summary
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in patients with liver disease related to chronic hepatitis C infection. The study will compare the investigational supplement with an active control (whey protein alone) to determine whether the combination formulation provides additional benefits on liver-related biomarkers and clinical assessment. The full summary is on the listing.
Where, as registered
No US site; Mexico (2).
Not yet recruitingNCT06683534
Palmitic Acid and Human Microvascular Function
Phase 2
Medical College of Wisconsin
About 40 people
Starts Jul 2026 (estimated)
In plain words A Phase 2 study of quercetin in people 18 to 40, run by Medical College of Wisconsin. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40. Conditions: Microvascular Dysfunction; Microvasculature; Cardiovascular Diseases; Cardiovascular Diseases (CVD); Microvascular Health; Obesity and Overweight.
Obesity (BMI>30)
Aged 18-40 years
English Speaking
The exclusion criteria are on the listing.
What it tests, as registered
Quercetin (dietary supplement); Placebo
Registered summary
The goal of this study is to learn how a supplement Quercetin can affect microvascular function. Participants will: * give two blood draws of 5 mL each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.